- Home
- RRR vs XENE Comparison
RRR vs XENE Comparison
Compare RRR & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- XENE
- Stock Information
- Founded
- RRR 1976
- XENE 1996
- Country
- RRR United States
- XENE Canada
- Employees
- RRR N/A
- XENE N/A
- Industry
- RRR Hotels/Resorts
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- XENE Health Care
- Exchange
- RRR Nasdaq
- XENE Nasdaq
- Market Cap
- RRR 2.6B
- XENE 2.3B
- IPO Year
- RRR 2016
- XENE 2014
- Fundamental
- Price
- RRR $50.23
- XENE $32.05
- Analyst Decision
- RRR Buy
- XENE Strong Buy
- Analyst Count
- RRR 13
- XENE 11
- Target Price
- RRR $54.62
- XENE $54.82
- AVG Volume (30 Days)
- RRR 706.0K
- XENE 977.8K
- Earning Date
- RRR 07-22-2025
- XENE 08-07-2025
- Dividend Yield
- RRR 3.99%
- XENE N/A
- EPS Growth
- RRR N/A
- XENE N/A
- EPS
- RRR 2.60
- XENE N/A
- Revenue
- RRR $1,947,975,000.00
- XENE $7,500,000.00
- Revenue This Year
- RRR $1.13
- XENE N/A
- Revenue Next Year
- RRR $2.70
- XENE $253.71
- P/E Ratio
- RRR $19.29
- XENE N/A
- Revenue Growth
- RRR 9.48
- XENE N/A
- 52 Week Low
- RRR $35.09
- XENE $26.74
- 52 Week High
- RRR $61.73
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- RRR 60.45
- XENE 51.34
- Support Level
- RRR $47.57
- XENE $31.22
- Resistance Level
- RRR $50.47
- XENE $33.46
- Average True Range (ATR)
- RRR 1.25
- XENE 1.28
- MACD
- RRR -0.03
- XENE 0.27
- Stochastic Oscillator
- RRR 69.31
- XENE 68.60
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.